EAU25 Interview Highlights | Prof. Samson Chan & Prof. Junlong Zhuang on PARPi in mHSPC

 EAU25 Interview Highlights | Prof. Samson Chan & Prof. Junlong Zhuang on PARPi in mHSPC

2025.04.10
At the 2025 EAU Congress, Prof. Junlong Zhuang (Nanjing Drum Tower Hospital) and Prof. Samson Chan (Department of Surgery, Tuen Mun Hospital, Hong Kong) sat down with Urology Frontier to discuss new insights from the Phase II PROact study. The study evaluated a triple combination of olaparib + abiraterone + prednisone in metastatic hormone-sensitive prostate cancer (mHSPC). According to the professors, early data show promising efficacy and manageable safety—suggesting PARP inhibitors may soon have a role beyond mCRPC in the prostate cancer treatment landscape. A potential step forward in precision therapy for prostate cancer. Watch the full interview now to hear their perspectives on the evolving role of PARPi in mHSPC.
EAU 2025 | Optimizing Prostate Biopsy Approaches: Prof. Kan Gong’s Team’s Peri-lesion Biopsy RCT Study Awarded at EAU

EAU 2025 | Optimizing Prostate Biopsy Approaches: Prof. Kan Gong’s Team’s Peri-lesion Biopsy RCT Study Awarded at EAU

2025.04.10
At the 40th Annual European Association of Urology (EAU) Congress, precision biopsy strategies and technological innovation were core topics in the prostate cancer field. With a focus on addressing the limitations of traditional systematic biopsies and MRI-targeted biopsies, multiple studies concentrated on optimizing biopsy approaches to balance diagnostic efficacy and safety. "UroStream" invited Professors Kan Gong and Yi Liu from Peking University First Hospital, along with Dr. Ruiyi Deng, to discuss the latest advancements in prostate cancer biopsy at the EAU conference, their team’s peri-lesion biopsy RCT study findings, and cutting-edge precision biopsy approaches.
Professor Aiwen Wu：Should a “Watch and Wait” Approach Be Considered Before Treating Low Rectal Cancer?    | Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee

Professor Aiwen Wu：Should a “Watch and Wait” Approach Be Considered Before Treating Low Rectal Cancer?    | Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee

2025.04.09
In the treatment of low rectal cancer, the “watch and wait” strategy has sparked a compelling debate between organ preservation and radical resection. With the advancement of neoadjuvant therapies, some patients achieve clinical complete response (cCR) following chemoradiotherapy, opening the door to non-operative management and the possibility of avoiding a permanent stoma. However, concerns over local regrowth, subjective response assessment, and the psychological burden on patients continue to challenge the broader application of this approach.